This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 11-17 February 2024, and includes updates on SARS-CoV-2 variant classification, diphtheria, chikungunya, dengue, influenza A(H5N1), a human case of co-infection with seasonal influenza A(H3N2) and avian influenza A(H10N5), Middle East respiratory syndrome coronavirus (MERS-CoV), and an overview of respiratory virus epidemiology in the EU/EEA.
In 2024, and as of 31 of January, approximately 10 000 CHIKVD cases and no deaths have been reported worldwide. A total of eight countries reported CHIKVD cases from the America (6) and Asia (2).
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
This report presents the available data for describing the current situation regarding HIV prevalence among sex workers, and the efforts being made across Europe and Central Asia towards HIV prevention among this population.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 21-27 January 2024 and includes updates on SARS-CoV-2, influenza, cholera, chikungunya, dengue and zika.
More frequent heatwaves and flooding, longer and hotter summers - all of these factors created more favourable conditions for mosquitos to thrive. Watch our animation, learn more and stay safe!
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 10-16 December 2023 and includes updates on measles, chikungunya, dengue, SARS-CoV-2, diphtheria, West Nile virus, respiratory virus epidemiology and influenza.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 26 November - 2 December 2023 and includes updates on human infection with influenza A(H1N2)v, influenza A(H5N1), an overview of respiratory virus epidemiology in the EU/EEA, respiratory infections due to Mycoplasma pneumoniae in the EU/EEA, HIV/AIDS surveillance 2023 (2022 data), West Nile virus, SARS-CoV-2 variant classification, and poliomyelitis.